



New Therapies Subgroup



Date of original recommendation: 21st October 2008

Date Re-reviewed: 24th January 2014

Metoject ® for the treatment of moderate to severe rheumatoid arthritis.

The New Therapies Subgroup discussed the above drug at a meeting on the 21st June 2011 and 24th January 2014. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Metoject ® for the treatment of moderate to severe rheumatoid arthritis.

The group recommends that Metoject ® may be considered as a treatment option for patients in whom parenteral methotrexate is indicated. Prior to any home treatment with parenteral methotrexate being initiated there must be a clear protocol in place that defines who is responsible for blood monitoring of therapy.

While the use of Metoject may increase drug costs it is envisioned that this would be offset by savings made through reducing the need for weekly hospital attendance.

Review date: October 2018

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.